WO1987006098A1 - Procede de preparation d'une composition pharmaceutique a liberation entretenue, et composition preparee par ce procede - Google Patents

Procede de preparation d'une composition pharmaceutique a liberation entretenue, et composition preparee par ce procede Download PDF

Info

Publication number
WO1987006098A1
WO1987006098A1 PCT/US1987/000780 US8700780W WO8706098A1 WO 1987006098 A1 WO1987006098 A1 WO 1987006098A1 US 8700780 W US8700780 W US 8700780W WO 8706098 A1 WO8706098 A1 WO 8706098A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
theophylline
process according
composition
ring
Prior art date
Application number
PCT/US1987/000780
Other languages
English (en)
Inventor
Richard James Harwood
Gunvant Nathubhai Mehta
Ramesh Chandra Jhawar
Liang-Lii Huang
Wayne Martin Grim
Shun Por Li
Original Assignee
Rorer International (Overseas) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer International (Overseas) Inc. filed Critical Rorer International (Overseas) Inc.
Publication of WO1987006098A1 publication Critical patent/WO1987006098A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Definitions

  • This invention relates to a pha ⁇ r-ace-tical ' composition of the type which is effective in releasing into the body biologically active material(s) over a prolonged period of time, and to a process for the preparation of said type of composition.
  • a particular aspect of the present invention relates to a process for the preparation of a composition which is effective in releasing theophylline or a derivative thereof into the body over a prolonged period of time.
  • Theophylline and derivatives thereof are known biologically active materials which are used, for example, as bronchodilators. It has long been recognized that theophylline tends to cause problems when administered in orally neat form. Gastrointestin ⁇ al, CNS and cardiovascular side effects due to excessive blood concentrations are not uncommon.
  • an enteric and controlled release form that is, a form in which a predetermined dose of theophylline is provided with an enteric matrix and coating which enables it to release theophylline into the stomach and to pass into the intestine where the theophylline is released at a controlled rate over a relatively long period of time, for example, over a 6- to 12-hour period.
  • enteric-coated and sustained release medicaments including theophylline
  • enteric-coated and sustained release medicaments are described in U.S. Patent Nos: 3,109,775; 4,083,949; and 4,261,970; and in PCT application bearing Publication No. WO 83/00284.
  • the aforementioned patents disclose a pharmacologically-active material encased in a slowly dissolvable coating or in a porous material which is insoluble in the acid environment of the stomach and which allows the active material to pass therethrough and into the intestine.
  • a typical sustained-release preparation comprises an inert core, such as a sugar grain, coated with an adhesive which has applied thereto a pharmacologically active substance.
  • the amount of active substance may be built up by forming layer upon layer of the adhesive coating and active substance. Once the desired amount of active substance has been applied, the multi-layered structure is covered with a permeable membrane which resists dissolution and otherwise being degraded in the stomach and in the intestine and which allows the desired pharmaceutical substance, for example, theophylline to pass through the pores thereof as it is dissolved by the- liquid solvent of the intestine.
  • Sustained release compositions are generally prepared by the use of successive coatings of different materials which provide for a gradual release of a pharmacologically active material by the peeling away of successive layers of materials, each of which has been painstakingly applied.
  • the coating methods which result in such a composition may be effected in a rotating coating pan commonly used for the manufacture of sugar-coated pills.
  • a sustained release theophylline preparation is prepared by applying to a batch of seed particles an alkali soluble adhesive in liquid form, followed by the addition of finely divided particles of solid theophylline. More specifically, the method involved:
  • the pan coating technique exhibits many of the properties desired in a sustained release preparation, the pan coating process involved more than about two dozen repeated and time consuming layering and drying steps.
  • Fluidized bed and column techniques have also been used to prepare sustained release compositions. In these techniques, seed particles are suspended by a stream of air and coated by the addition of adhesives and powdered ingredients, and also involve numerous layering steps which are time consuming and cost ineffective.
  • a Glatt column air suspension system is used to apply to suspended seed par ⁇ ticles multi-layers of a liquid suspension of theophylline and polyvinylpyrrolidone and isopropanol. The multi-layered product is then coated with a mixture of cellulose materials. It has been reported that the product believed to be prepared according to the aforementioned process exhibits an inhibited release pattern when administered concurrently with or shortly after the ingestion of food.
  • a process for the preparation of a sustained release pharmaceutical composition including a seed particle coated with a pharmaco ⁇ logically active compound-containing layer, comprising
  • composition of the present invention relates to a sustained release composition, which under the influence of gastrointestinal juices releases a pharmacologically active ingredient at a desired rate, and which comprises a seed core, a single layer including said pharmacologically active ingredient, and an encapsulating coating capable of forming pores.
  • a particularly preferred aspect of the composition of the present invention relates to the relatively invariant release character ⁇ istics thereof under fasting and/or meal ingestion conditions.
  • Still another aspect of the present invention relates to a method for the treatment of physiological disorders, for example, bronchial disorders such as asthma, comprising the oral ingestion by an individual of a pharmaceutical composition, as described above, wherein said preparation may be administered at prescribed intervals independent of the presence or absence of food in said individual's digestive tract.
  • physiological disorders for example, bronchial disorders such as asthma
  • Figure 1 is a partial sectional side elevational view of a circular mixing and granulating device showing a particle fluidizing and coating process in accordance with the present invention.
  • Alkali soluble material means a material which is soluble in the alkaline conditions of the intestine and of the type suitable for use in forming a sustained release pharmaceutical and which is capable of functioning as a binder to agglomerate particles of a pharmacologically active compound in forming a coating of the sustained release composition of the present invention.
  • Enteric coating means a coating which permits a medicament to pass through the stomach substantially without being released in the stomach fluids.
  • Membrane means a semipermeable structure permitting the passage therethrough of water and other like sized molecules.
  • Non-enteric coating means a coating which permits the release of a medicament in the stomach and which may be a continuous, discontinuous, irregular or spotty coating.
  • Pore means an opening which permits the passage therethrough of molecules of a size larger than water.
  • Seed is a small particle of material of the type that is suitable for use in sustained release pharmaceutical compositions, and have a mean particle size of a-bout 600 to about 850 microns.
  • An example of such a material is a combination of sugar and cornstarch.
  • Theophylline means theophylline and derivatives thereof which are effective bronchodilators for the relief of asthma, including, for example, guaithylline (3,7-Dihydro-l,3-dimethyl- lH-purine-2,6-dione compounded (1:1) with 3-(2-methoxyphenoxy)- 1,2-propanediol).
  • a desired amount of seed- particles 7 is introduced into the chamber 1 ⁇ of the mixing and coating device shown in Figure 1 ⁇ while the rotor disc 2 rotates about the shaft 3_ and a positive fluid pressure, shown as arrow 8_, is applied through clearance 4.
  • the fluid comprises preferably an inert gas, such as air, nitrogen or carbon dioxide and emanates from a source not shown in Figure :L.
  • the rotating rotor disc 2 imparts a centrifugal force to the seed particles 7 propelling them towards the chamber wall 5 ⁇ where the pressure of the upwardly moving fluid, shown as arrow 8_, imparts to the particles 7 upward movement in substantial opposition to the force of gravity.
  • the chamber wall 5 of the embodiment of the device shown in Figure 1 comprises an outwardly inclined portion 5a and an inwardly inclined portion 5b.
  • the outwardly inclined portion 5a can function together with the raising and lowering the rotor disc 2 so as to control the fluid volume passing through clearance 4, while the inwardly inclined portion 5b functions to deflect the upwardly moving particles 7_ toward the . central portion of the chamber :L.
  • the particles 7 rise in the chamber 1 ⁇ until the force of gravity overcomes the decreasing force of the fluid pressure.
  • the particles 7_ then fall towards the central portions of the rotor disc 2.
  • the motion of the seed particles 7_ is depicted in two dimensions in Figure 1 ⁇ by lines U, D and 0, and the resulting shape and motion of the seed particles 7_ is referred to throughout this application as a "fluidized ring".
  • the particles 7 are not confined to two dimensions but also rotate about within the volume of the fluidized ring as a result of the rotation of the disc.
  • a liquid coating composition including . the pharmacologically active material and alkali soluble material is introduced into the chamber 1 ⁇ by suitable means such as one or more spraying nozzles.
  • the liquid coating composition is thereby contacted with the seed particles 7 as the particles rotate about the chamber and pass through the space where the coating composition is introduced into the ring.
  • the preferred method of coating the seed particles 7 comprises the sprayirig of a fine spray mixture of " air and the atomized liquid coating composition through the nozzle 6_, and the coating of the particles occurs initially as the particles pass within the volume of sprayed coating composition emanating from the inlet nozzle 6_.
  • the liquid coating composition includes a diluent such as a lower alkyl alcohol or low boiling haloalkyl solvent, with preferred diluents being ethanol, isopropanol and methylene chloride and mixtures thereof.
  • a diluent such as a lower alkyl alcohol or low boiling haloalkyl solvent, with preferred diluents being ethanol, isopropanol and methylene chloride and mixtures thereof.
  • water may be included in the coating composition for the purpose of controlling the amount of static electricity generated during the coating process and in quanti ⁇ ties effective for this purpose. It has been determined that the effective anti-static amounts of water can be used in the coating compositions without adversely affecting the dissolution rate of the sustained release composition.
  • the rate of spraying into the fluidized ring should be sufficient to uniformly distribute the coating composition throughout the fluidized ring of seed particles and is dependent on the number of spray nozzles used in the process, the amount of the seed particles contained in the fluidized ring as well as the form of, the viscosity of and the nature of the coating composition. Typical spraying rates range from about 50 to about 700 g/min/nozzle.
  • the coating composition comprises a suspension of solid particles of pharmacologically active material in a liquid dispersant com ⁇ prising a lower alkyl alcohol.
  • the suspension also includes the alkali soluble material in either liquid or solid form.
  • the lower alkyl alcohol facilitates the admixture of the suspension with the fluidized ring of seed particles 7 as well as the ⁇ log- free spraying of the suspension.
  • the lower alkyl alcohol may be ethanol(denatured and/or 200 proof), isopropanol, n-propanol or a mixture of both.
  • the size of the solid particles of pharmacologically active material has a measurable effect on the sustained release properties of the final product. It is preferred, in order to optimize the release rate of the pharmacologically active material, that the size of the solid particles of pharmaco ⁇ logically active material be "micronized", that is on the order of less than about one to about 50 microns, or a size measured on the order of about 300 mesh or more, based on the micromerogragh system of measurement.
  • the suspension include a percentage amount of solid pharmacologically active particles that will facilitate and promote the spraying of the suspension into the fluidized ring. It is believed that an effective amount of solid particles in the suspension can be from about 30g to about 60g per 100 g of suspension and is preferably about 40g to about 55g per 100 g of suspension. It is also advantageous to coat the seed particles with an amount of pharmacologically active particles that will form a complete and continuous coating of agglomerated particles on the surface thereof. It should be understood that the total amount of the pharmacologically active particles in the sustained release composition should be suf ⁇ ficient to provide a source of active material throughout the desired sustained release period.
  • the composition can comprise from about 40 to about 90 wt% and preferably about 50 to about 65 wt% of such active material based on the total dried weight of the composition.
  • the rotational rate of the rotor shaft 3 and the positive fluid pressure 8_ are controlled in order to provide the ap ⁇ intestinalte conditions for the creation of a " * flu.idized ring" of solid particles 7_-and for the layering of coating materials onto the seed particles in a uniform manner.
  • Typical rotor speeds range from about 100 to about 300 rpm and are preferably within the range of about 120 to about 200 rpm and may vary within these ranges during the course of the coating process.
  • the fluid pressure depends on the amount of material introduced into the chamber 1 ⁇ and can range from about 30 to about 60.psi.
  • the temperature of chamber 1 ⁇ and of the inert gas passing through the clearance 4 are controlled,, throughout the coating process.
  • the fluidized ring and the inert gas are heated and maintained at a temperature within a range sufficient to volatilize the diluent contained in the coating compositions at a rate which permits the uniform coating of the seed particles.
  • an effective temperature for the inert gas is about 30 to about 75°C, and preferably at about 35 to about 50°C, while an effec ⁇ tive temperature for the fluidized ring is about 20 to about 45°C and preferably about 25 to about 35°C.
  • E xemplary equipment which can be used in the present process include the Rotor Granulators sold by Glatt Air Techniques, Inc. and the Vector/Freund Spir-a-Flow sold by Vector Corporation.
  • the Spir-a-Flow equipment introduces into the coating process an additional force which is derived from air pressure passing through numerous perforations in the inner portion of the rotor disc. This additional force creates eddies and currents in the inner volume of the fluidized ring and serve to increase the rate and improve the efficiency of the coating operation.
  • This additional coating comprises a porous membrane having pores of a size sufficient to permit a pharmacologically active compound such as theophylline to pass therethrough, may be formed by (C) charging a fluidized ring containing said coated seed particles prepared by step (B) above with a porous membrane-forming solution comprising a mixture of an alkali insoluble and acid insoluble component and a water soluble component.
  • the mixture from which the porous membrane is formed comprises an acid insoluble and alkali insoluble material not otherwise degradable in the environments of both the stomach and intestine and a water soluble material which in the aqueous environment of the stomach and intestine dissolves to form pores in the membrane.
  • the ratio of membrane-forming material to water soluble material in the membrane and membrane- forming solution is about 5:1 to about 20:1, and more preferably about 8:1 to" about 15:1.
  • Exemplary of such porous membrane- forming solutions are those comprising about 5 to about 10 g, and preferably about 6 to about 8 g of acid insoluble, alkali insoluble material per 100 g of coating solution, and about 0.5 to about 1 g and preferably about 0.6 to about 0.8 g of water soluble material per 100 g of coating solution.
  • the amount of membrane-forming material combined with the particles coated in step (B) above may range from about 0.1 to about 2%, and preferably about 0.3 to about 1.3% of the total dried weight of the composition.
  • a uniform membrane is desireable. It is believed that such a membrane provides for a reproducible and controlled rate of dissolution of the underlying pharmaco ⁇ logically active material. It has been determined that the use of dilute membrane-forming solutions result in more uniform membranes than more concentrated solutions. It has also been found that those compositions having more uniform membranes and containing less membrane-forming material possess desired sustained release properties while compositions having less uniform membranes require more membrane-forming material to exhibit similarly desired release properties. Accordingly, for many applications of the present invention, the use of a less concentrated porous membrane-forming solution can reduce the total amount of membrane-forming material incorporated into the present sustained release composition to obtain its desirable sustained release properties.
  • the membrane can be formed by combining the coated seed particles with a liquid solution comprising a solvent which has dissolved therein said mixture of materials.
  • exemplary solvents include lower alkyl alcohols such as ethanol(denatured and 200 proof), isopropanol or n-propanol or haloalkyls such as methylene chloride or carbon tetrachloride.
  • a solid pore-forming membrane is formed from the solution as the solvent evaporates.
  • the acid insoluble and alkali insoluble membrane-forming material a cellulose ether, most preferably a lower alkyl cellulose ether, for example, ethyl cellulose.
  • a lower alkylene glycol for example, propylene glycol.
  • the porous membrane of the resulting sustained release composition comprises ethyl cellulose and propylene glycol.
  • the porous membrane-forming solution is applied to the coated seed particles by spraying the solution into a fluidized ring comprising seed particles coated in step (B) above.
  • the rate of spraying may differ from that used for the coating of step (B) due to the differences between the two liquid spray formulations including the amounts of materials in the respective liquid compositions as well as the differences in the desired thickness of each layer or coating.
  • the rate may also vary as a function of the size of the batch of material being processed in the chamber.
  • the membrane-forming solution is applied at a rate which can range from about 20 to about 1000 g/min/per nozzle, and in most preferred applications at a rate of about 20 to about 500 g/min/per " nozzle.
  • the motion of the fluidized ring of coated particles is maintained and heating is continued in order to dry the coated particles and remove volatile diluents included in the spraying compositions.
  • the complete drying of the coated particles may be accomplished as an operation contiguous with the coating operation conducted in the chamber 1 ⁇ , but certain considerations including the nature of the diluent, the desired thickness of the coating and the mechanical limitations on the mixing apparatus may require a separate drying operation. For the applications where these considerations prevail, the partially dried coated particles are removed from the chamber 1 ⁇ and their drying is completed in a separate drying device such as a hot air oven or the like.
  • a special embodiment of the present invention comprises a composition having an outermost coating which permits the aqueous contents of the stomach to penetrate therethrough and dissolve from the underlying membrane an amount of water soluble material MISSING ON FILING
  • percent of the materials deposited by this coating solution based on the total weight of the coated particle can range, for example, from about 0.05 to about 0.7 % w/w.
  • Two exemplary formulations for the non-enteric coating solution are described by the following formulations where the amounts of ingredients are given per 100 gram of solution.
  • Formulation 1 Formulation 2 Amount per 100 g Amount per 100 g ethyl cellulose lOcps 0.1 g 2.4 g pharmaceutical glaze 0.6 g 13.8 g (total shellac solids) (0.2 g) (4.8 g) denatured ethanol 0.6 g q.s. methylene chloride q.s.
  • the seed particle comprising the core of the.sustained release composition also comprises a pharmaceutically active material.
  • the use of a particle of pharmaceutically active material having a mean particle size of about 600 to about 850 microns as the seed particle may provide a convenient higher dosage form of the present composition.
  • about 10 to about 100 % more of pharmaceutically active material may be included in a standard volume of sustained release pellets prepared using pharmaceutically active seed material.
  • Such compositions may be described as "higher assay" sustained release compositions.
  • Example 1 It is believed that the present invention will find particu ⁇ larly wide use in the preparation of a sustained release composi ⁇ tion comprising theophylline as a pharmacologically active ingredient therein.
  • the following examples describe a method for preparing theophylline sustained-release pharmaceutical compositions in accordance with the present invention.
  • Example 1
  • a preferred theophylline-containing composition is prepared utilizing the following ingredients in the amounts indicated below.
  • total shellac solids content (16 g) ethyl cellulose 10 cps 0.4 g propylene glycol USP 0.04 g denatured ethanol qs
  • the micronized theophylline anhydrous powder is dispersed in about 40 g of pharmaceutical glaze and about 37 g of denatured ethanol in a mixer or homogenizer.
  • a Glatt Rotor Granulator (Model RGR-5) fitted with a Glatt GPCG 5/9 coating device and having parts like those shown in the apparatus of Figure 1 ⁇ is used to coat the non-pareil seeds, which are charged into the chamber 1_.
  • the rotor speed is set and maintained at 150 rpm
  • the air pressure is set at 1,100 m 3 per hour
  • the temperature of the inlet air volume is set at about 40°C
  • the fluidized ring temperature is set at about 30°C .
  • the slurry of theophylline is sprayed into the fluidized ring through two nozzles at a rate, which varies within the range of about 50 to about 500 g/min., but which averages at about 200 g per minute.
  • About 5 g of pharmaceutical glaze, containing 35 % shellac solids, and about 4 g of denatured alcohol are added to the last 10% of the slurry prior to spraying into the fluidized ring.
  • rotation is continued and the theophylline- shella ⁇ pellets dried by increasing the temperature and adjusting the inlet air volume for about 10 to about 30 minutes.
  • the pellets are removed from the chamber and sifted to collect the 12/20 fraction, which is dried in a hot-air oven at about 70°C for about 15 to about 24 hours.
  • the dried 12/20 fraction of pellets is reintroduced into the rotor granulator and the temperature, the rotor speed and the inlet air-volume adjusted to produce a fluidized ring.
  • An alcoholic solution in which each 100 g of solution contained 7g of ethyl cellulose and 0.8g of propylene glycol is sprayed into the fluidized ring until the ethyl cellulose content of the coated particles reaches about 0.4 % by weight. After the spraying is completed, the temperature of the inlet air is increased to about 50°C while the rotation is continued for about 5 to 10 minutes.
  • a preferred high assay theophylline-containing composition is prepared utilizing the following ingredients in the amounts indicated below.
  • total shellac solids content (16 g) ethyl cellulose 10 cps 0.4 g propylene glycol USP 0.04 g denatured ethanol qs
  • the micronized theophylline anhydrous powder is dispersed in about 46 g of pharmaceutical glaze and about 42 g of denatured ethanol in a mixer or homogenizer.
  • a Glatt Rotor Granulator (Model RGR-5) fitted with a Glatt GPCG 5/9 coating device and having parts like those shown in the apparatus of Figure 1 ⁇ is used to coat 24g of the theophylline 25/30 mesh powder, which are charged into the chamber 1 ⁇ .
  • the rotor speed is set and main ⁇ tained at 150 rpm, the air pressure is set at 1,100 m 3 per hour, the temperature of the inlet air volume is set at about 40°C, and the fluidized ring temperature is set at about 30°C .
  • the slurry of theophylline is sprayed into the fluidized ring through two nozzles at an increasing rate, which varies within the range of about 50 to about 500 g/min. After all of the slurry is sprayed, rotation is continued and the theophylline-shellac pellets dried by increasing the temperature and adjusting the inlet air volume for about 10 to about 30 minutes. The pellets are removed from the chamber and sifted to collect the 12/20 fraction, which is dried in a hot-air oven at about 70°C for about 15 to about 24 hours. The dried 12/20 fraction of pellets is reintroduced into the rotor granulator and the temperature, the rotor speed and the inlet air-volume adjusted to produce a fluidized ring.
  • the pellets prepared according to Example 2 above are maintained in the rotor granulator for about 5 minutes after the last described spraying step has been completed at which time a n alcoholic solution containing ethyl cellulose(2.4 g), pharmaceutical glaze(13.8g) in each lOOg of denatured alcohol is sprayed into the mixing chamber until the solids content of the outermost coating reaches 0.15 % by weight.
  • a n alcoholic solution containing ethyl cellulose(2.4 g), pharmaceutical glaze(13.8g) in each lOOg of denatured alcohol is sprayed into the mixing chamber until the solids content of the outermost coating reaches 0.15 % by weight.
  • the temperature of the inlet air is increased to about 50°C and rotation continued for about 5 to 10 minutes.
  • the coated pellets prepared according to Examples 1, 2 or 3 may be encapsulated or formed into tablets.
  • the dissolution characteristics of the pellets prepared according to the present process have been determined in the laboratory using a dissolution apparatus equipped to measure the concentration of dissolved pharmaceutical material as a function of time and as a function of the pH of surrounding fluids.
  • the time-dependant, pH-constant, dissolution characteristics of the theophylline-containing compositions prepared in accordance with the process described in Examples 1 and 2 above and containing about 0.4 w/w% ethyl cellulose in the porous membrane layer are presented in Table 1 below.
  • Table 2 below presents the time- and pH-dependant dissolution characteristics of the theophylline pellets prepared according to Example 1 above.
  • the data presented in the tables below is expressed as a percent of the theophylline dissolved in the pellets and demonstrates the steady release of theophylline from the composition to provide a non- fluctuating supply of theophylline over a period of time to the blood stream of a patient.
  • the apparatus paddles are set at 50 rpm.
  • the solution in which six capsules of the composition are dissolved comprises initially 900 ml of a pH 3 buffer, which is changed to pH 7.4 after 3.5 hours by the addition of sodium hydroxide.
  • a - dissolution medium comprises 0.1 N HC1.
  • b - dissolution medium comprises 0.05 M sodium acetate and 0.05M monobasic potassium phosphate, which is adjusted to the stated pH by the addition of HC1 or NaOH.
  • the controlled release and bioavailability characteristics of the preferred theophylline-containing compositions of the present invention enable the asthma patient to ingest a predeter ⁇ mined dosage amount about once or twice a day and to thereby maintain a therapeutic level of active ingredient in the bloodstream.
  • the present invention can be formulated to provide a controlled release composition which maintains a relatively invariant steady state concentration of active ingredient in the blood. Fluctuations in blood levels of the active ingredient are reduced, and accordingly, the therapeutic effect increased and side effects lessened.
  • composition aspect of the present invention relates to a sustained release composition in which the pharmacologically active material such as theophylline is contained in a single coating of a multi-coated pellet and which provides a sustained release thereof over a period of about 12 hours.
  • a special embodiment of the composition aspect of this invention is a higher assay composition wherein the pharmaceutically active material also comprises the seed core of the pellet.
  • a preferred embodiment of the composition aspect of the present invention comprises a theophylline-containing pharmaceutical composition which is particularly suitable for the treatment of individuals suffering from bronchial disorders such as asthma in that it provides a means for maintaining a therapeutically effective amount of theophylline in the bloodstream over extended periods of time, for example, up to 12 hours regardless of the timing or frequency of food intake.
  • This preferred embodiment comprises a composition prepared according to the process described above including an outermost non-enteric coating.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le procédé de préparation d'une composition pharmaceutique à libération entretenue consiste à former un anneau fluidisé (O) (U) (D) de particules (7) et à mettre en contact lesdites particules maintenues en suspension dans l'anneau avec une composition liquide contenant un matériau pharmaceutiquement actif et un matériau soluble dans un alcali.
PCT/US1987/000780 1986-04-07 1987-04-07 Procede de preparation d'une composition pharmaceutique a liberation entretenue, et composition preparee par ce procede WO1987006098A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84899186A 1986-04-07 1986-04-07
US848,991 1986-04-07

Publications (1)

Publication Number Publication Date
WO1987006098A1 true WO1987006098A1 (fr) 1987-10-22

Family

ID=25304802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/000780 WO1987006098A1 (fr) 1986-04-07 1987-04-07 Procede de preparation d'une composition pharmaceutique a liberation entretenue, et composition preparee par ce procede

Country Status (4)

Country Link
JP (1) JP2541835B2 (fr)
AU (1) AU7280387A (fr)
CA (1) CA1309022C (fr)
WO (1) WO1987006098A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413782A (en) * 1990-12-19 1995-05-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding pharmaceuticals to ion exchange resins
EP0716853A1 (fr) * 1994-12-16 1996-06-19 Societe Des Produits Nestle S.A. Formulation de cafféine à libération prolongée
EP1142569A2 (fr) * 1995-10-19 2001-10-10 Biogram AB Enrobage de petites particules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3109775A (en) * 1961-01-31 1963-11-05 Key Pharma Theophylline-noscapine sustained release composition for treatment of asthma
WO1983000284A1 (fr) * 1981-07-15 1983-02-03 Key Pharma Theophylline a liberation prolongee
US4588366A (en) * 1981-04-13 1986-05-13 Werner Glatt Rotation granulator
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3109775A (en) * 1961-01-31 1963-11-05 Key Pharma Theophylline-noscapine sustained release composition for treatment of asthma
US4588366A (en) * 1981-04-13 1986-05-13 Werner Glatt Rotation granulator
WO1983000284A1 (fr) * 1981-07-15 1983-02-03 Key Pharma Theophylline a liberation prolongee
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413782A (en) * 1990-12-19 1995-05-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding pharmaceuticals to ion exchange resins
EP0716853A1 (fr) * 1994-12-16 1996-06-19 Societe Des Produits Nestle S.A. Formulation de cafféine à libération prolongée
WO1996018389A1 (fr) * 1994-12-16 1996-06-20 Societe Des Produits Nestle Sa Formulation de cafeine a liberation prolongee
US5700484A (en) * 1994-12-16 1997-12-23 Nestec S.A. Sustained release microparticulate caffeine formulation
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
EP1142569A2 (fr) * 1995-10-19 2001-10-10 Biogram AB Enrobage de petites particules
EP1142569A3 (fr) * 1995-10-19 2003-05-21 Jagotec Ag Enrobage de petites particules
EP1716849A1 (fr) * 1995-10-19 2006-11-02 Jagotec Ag Enrobage de petites particules

Also Published As

Publication number Publication date
JPH01501936A (ja) 1989-07-06
JP2541835B2 (ja) 1996-10-09
AU7280387A (en) 1987-11-09
CA1309022C (fr) 1992-10-20

Similar Documents

Publication Publication Date Title
US5026709A (en) Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
AU727018B2 (en) Galenic form with extended release of milnacipran
EP0475536B1 (fr) Granules sphériques à noyau et leur fabrication
US5824339A (en) Effervescent composition and its production
US5260072A (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
KR101245627B1 (ko) 산제의 맛 차단
US4892740A (en) Orally administrable pharmaceutical preparation of improved flavoring characteristics
IE69042B1 (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
IE911752A1 (en) Taste masking and sustained release coatings for pharmaceuticals
JP2003509439A (ja) 水性コーティングされたビーズレットの製法
JPH06508779A (ja) ビーズレット形の医薬物質の製法
EP0317274B1 (fr) Comprimé médicinal à mâcher contenant des moyens pour le masquage du goût
EP1278514B1 (fr) Formulations micro-encapsulees et a liberation prolongee a base d'herbes medicinales
EP0156243B1 (fr) Composition à libération contrôlée et sa préparation
US5460825A (en) Taste mask coatings for preparing chewable pharmaceutical tablets
EP0083372A1 (fr) Theophylline a liberation prolongee.
AU633757B2 (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
CA2079934C (fr) Enrobages permettant de masquer le gout de comprimes pharmaceutiques machables
WO2003015758A1 (fr) Micro-pastilles a liberation prolongee et procede permettant leur production
WO1987006098A1 (fr) Procede de preparation d'une composition pharmaceutique a liberation entretenue, et composition preparee par ce procede
US9333170B2 (en) Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof
EP2749273A1 (fr) Préparation solide orale à libération modifiée
MXPA99002022A (en) Galenic formula with extended release of milnacipran

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE